Research summaries for everyoneNot medical advice
NAD+ research reference vial, Elevated Pharma

Research reference · Cellular Energy

NAD+

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in cellular energy and redox reactions, not a peptide. Most human research tests its precursors, NR and NMN.

Published by Elevated Pharma ·

Cellular EnergyBiochemical reference

Identity

What is NAD+?

The oxidized form of nicotinamide adenine dinucleotide (also called nadide).

Research context

What has NAD+ been studied for?

Human randomized trials of NR and NMN measure blood NAD+ and metabolic markers. A 2026 Nature Metabolism study compared three precursors head to head.

Evidence boundary

What does the research not show?

Raising blood NAD+ is not the same as a clinical benefit, and precursor studies do not describe NAD+ itself given directly.

U.S. status · November 7, 2026

Is NAD+ FDA-approved?

No therapeutic or approved-product claim is made.

Research updates

What’s new

Dated developments for NAD+, newest first. See all research updates.

  1. Precursors compared head to head

    A randomized study in 65 adults found NR and NMN raised blood NAD+ over 14 days while nicotinamide did not.

    Read the source

Key studies

The main NAD+ research

Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.

Search all PubMed records for NAD+ · Counts and selections checked November 7, 2026.

Reference identifiers

NAD+ identity data

Database identity describes the reference substance, not any specific material or lot.

Primary name
NAD+
Also indexed as
Nicotinamide adenine dinucleotide / NAD / Nadide
PubChem CID
5892

Official & primary sources

Regulatory and database records

Citation does not imply an Elevated Pharma partnership or endorsement.